According to Reuters, Eli Lilly & Co. (NYSE: LLY) won a major battle against Teva Pharmaceutical Industries Limited (NASDAQ: TEVA), which had been petitioning for a generic version of Lilly’s drug, Evista. The court upheld the patent on Evista,...

Inhibitex Inc. (NASDAQ: INHX) was up $0.16 (11.27%) this morning to $1.58 on news that the company had completed a Phase1a, single ascending dose trial of its nucleotide polymerase inhibitor, INX-189.  The drug is currently being developed for the treatment...

Intendis, Bayer Healthcare’s dermatology sector, has signed a deal with Los Angeles-based biopharma company Kythera Biopharmaceuticals in which the company receives rights to Kythera’s lead product candidate, ATX-101, in areas outside of the...

Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is up 12.87% this morning after it announced that its PLX therapeutic stem cell line, derived from the material of a human placenta, would be the only type of cell selected for a study designed to prevent inflammatory...

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) was up $0.75 (9.14%) this morning to $8.96 following reports that by introducing an experimental drug during chemotherapy the company had succeeded to wipe out brain cancer cells in mice.  This news provides hope...

For the past several months, rumors and reports have flown about French pharmaceutical behemoth Sanofi-Aventis (NYSE: SNY) devoting heavy resources to acquiring American research company Genzyme Corporation (NASDAQ: GENZ). The firms have gone back and...

Swiss drugmaker Roche took a blow this past Friday after the U.S. FDA denied the company’s request for accelerated approval regarding trastuzumab-DM1, or T-DM1.  The drug, according to Reuters, “comprises ImmunoGen’s DM1 cancer-cell-killing...

GlaxoSmithKline’s (NYSE: GSK) new shingles recently entered phase III trials, and is expected to breeze through these as well. Meanwhile, Antigenics Inc. (NYSE: AGEN) the company responsible for the vaccine’s adjuvant, also experienced a major...

DARA Biosciences, inc. (NASDAQ: DARA) is on the chopping block after being notified by the SEC that the company didn’t meet the minimum equity requirement to continue to be publicly traded on the NASDAQ. The market’s minimum requirement is...

Sanofi-Aventis SA (NYSE: SNY) has raised it’s final offer for the purchase of Genzyme (NASDAQ: GENZ) to $70 a share, up one dollar from their initial offer of $69.  The price is certainly not one to thrill those at Genzyme, however insiders report...